NDAORALTABLET, ORALLY DISINTEGRATING
Approved
Apr 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
ZYPREXA ZYDIS (olanzapine) by Aurobindo Pharma is olanzapine, in the listed indications is unclear. Approved for schizophrenia, bipolar disorder, schizoaffective disorder and 2 more indications. First approved in 2000.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZYPREXA ZYDIS is an orally disintegrating tablet formulation of olanzapine, an atypical antipsychotic approved in 2000. It treats schizophrenia, bipolar disorder, schizoaffective disorder, and acute mania primarily through dopamine D2 and serotonin 5-HT2A receptor antagonism. Off-label use extends to treatment-resistant depression, dementia-related agitation, and metabolic complications including hyperglycemia and insulin resistance.
$3MPart D
LOE ApproachingProduct approaching loss of exclusivity with minimal Part D spending signals declining franchise momentum and likely restructured commercial team focus.
Mechanism of Action
olanzapine, in the listed indications is unclear. However, the efficacy of olanzapine in schizophrenia could be mediated through a combination of dopamine and serotonin type 2 (5HT 2 ) antagonism.
Pharmacologic Class:
Atypical Antipsychotic
Indications (5)
Worked on ZYPREXA ZYDIS at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.